Sign In
Buy PFE
$25.69
+0.335 (+1.32%)
At Close: Jun 04, 2026
Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports
03:02pm, Thursday, 20'th Feb 2025
Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends
08:45am, Thursday, 20'th Feb 2025
The S&P 500 is up 3.96% YTD, and I predict it could reach 7,000 by the end of 2025. The Dividend Harvesting Portfolio reached a new milestone with a 28.65% ROI, generating $2,010.09 in forward annuali
The Smartest Dividend Stocks to Buy With $1,000 Right Now
04:45am, Thursday, 20'th Feb 2025
You have $1,000 (or $200 or $50,000) burning a hole in your pocket and you're itching to invest in some stocks. Might I suggest some dividend payers?
10 Ideal 'Safer' January Dividend Buys, Out Of 40 Choices From Readers
06:07pm, Wednesday, 19'th Feb 2025
Before January 31, 2025, my REaders mentioned 40 equities in their comments on my articles. Some bad-news investments (ROgues) mixed with (mostly) FAvorites. Thus, readers spoke-up about the ReFa/Ro.
Why Pfizer's Stock Price Isn't Reflecting Its True Value
07:22am, Wednesday, 19'th Feb 2025
Pfizer's EPS and revenue beat my expectations, mainly due to strong sales of its anti-cancer medications. So, Xtandi sales amounted to $565 million in the fourth quarter of 2024, an increase of 79.9%
Pfizer Stock's Upside Got Bigger
03:31am, Wednesday, 19'th Feb 2025
Pfizer Stock's Upside Got Bigger
Pfizer CEO Albert Bourla: Focusing on opportunities outside of vaccines with RFK Jr.
05:18pm, Tuesday, 18'th Feb 2025
Albert Bourla, Pfizer CEO, joins CNBC's Angelica Peebles and 'Closing Bell Overtime' to talk the impact of tariffs, Pfizer's drug pipeline, vaccines and more.
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
11:33am, Tuesday, 18'th Feb 2025
PHILADELPHIA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Direct
Sticky Inflation Won't Go Away: 4 High-Yield Dividend Stocks That Always Work
07:45am, Tuesday, 18'th Feb 2025
While the recent inflation data is undoubtedly far better than the 9.1% increase printed in the summer of 2022, many Americans still face the reality that prices for everyday necessities like food, en
3 Things You Need to Know If You Buy Pfizer Today
04:35am, Tuesday, 18'th Feb 2025
Pfizer (PFE -0.43%) has been around for 175 years, but the company's revenue soared to its highest ever only in more recent times. Thanks to its coronavirus treatment and vaccine, the pharma giant rep
3 Magnificent Stocks to Buy That Are Near 52-Week Lows
05:44am, Monday, 17'th Feb 2025
Buy low, sell high. That has been a good strategy for investors for a long time.
Pfizer: Danuglipron Could Tip The Scale In A Few Years, But For Now, Sell
01:27am, Monday, 17'th Feb 2025
I rate Pfizer a sell for the next 18–24 months. I expect continued headwinds from Medicare Part D redesign and patent expirations for Eliquis and Prevnar-13 in 2026. Medicare changes will cut $1 bil
Buy 5 'Safer' Dividend Dogs Of 23 February Barron's Better Bets Than T-Bills
07:53am, Sunday, 16'th Feb 2025
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge d
The Big 3: AMSC, PFE, GOLD
01:53pm, Thursday, 13'th Feb 2025
Alan Knuckman turns to stocks he believes aren't as renowned as their peers. He explains why he's watching American Superconductor (ASMC), Pfizer (PFE), and Barrick Gold (GOLD) for today's Big 3.
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outcomes in Metastatic Castration Resistant Prostate Cancer
10:04am, Thursday, 13'th Feb 2025
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI®
